Theravance Biopharma, Inc.
TBPH
$17.05
-$0.01-0.06%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 35.11% | 68.20% | 66.92% | 27.12% | 24.49% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 35.11% | 68.20% | 66.92% | 27.12% | 24.49% |
| Cost of Revenue | -36.03% | -20.77% | -0.61% | 8.23% | 14.40% |
| Gross Profit | 114.27% | 210.21% | 161.99% | 52.95% | 38.05% |
| SG&A Expenses | -4.75% | 3.11% | 6.47% | 10.69% | 9.71% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.02% | -5.53% | 3.98% | 9.82% | 11.35% |
| Operating Income | 126.80% | 110.91% | 91.51% | 17.62% | 9.37% |
| Income Before Tax | 47.01% | 383.17% | 389.70% | 216.09% | 204.85% |
| Income Tax Expenses | -81.11% | 124.12% | 97.83% | 105.46% | 263.96% |
| Earnings from Continuing Operations | 312.92% | 296.36% | 287.70% | 159.40% | 128.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 312.92% | 296.36% | 287.70% | 159.40% | 128.54% |
| EBIT | 126.80% | 110.91% | 91.51% | 17.62% | 9.37% |
| EBITDA | 132.69% | 114.95% | 95.15% | 18.32% | 9.76% |
| EPS Basic | 331.61% | 291.21% | 281.11% | 156.96% | 126.61% |
| Normalized Basic EPS | -225.97% | 136.24% | 111.39% | 224.97% | 213.79% |
| EPS Diluted | 337.26% | 285.86% | 275.63% | 155.43% | 125.08% |
| Normalized Diluted EPS | -223.00% | 139.38% | 114.80% | 223.07% | 211.61% |
| Average Basic Shares Outstanding | 3.08% | 3.07% | 3.02% | 2.16% | -0.29% |
| Average Diluted Shares Outstanding | 4.59% | 5.17% | 5.13% | 3.15% | -0.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |